(ATHA) – Globe Newswire
-
Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer
-
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
-
Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting
-
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference
-
Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates
-
Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
-
Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update
-
Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
-
Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies
-
Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies
-
Athira Pharma to Participate in Sidoti December Small Cap Investor Conference
-
Athira Pharma Announces Upcoming Presentation at Motor Neurone Disease Association’s 34ᵗʰ International Symposium on ALS/MND
-
Athira Pharma Presents Preclinical Data Highlighting Fosgonimeton’s Neuroprotective Effects Against Amyloid-β-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer’s Disea
-
Athira Pharma Reports Third Quarter 2023 Financial Results and Pipeline and Business Updates
-
Athira Pharma to Participate in Jefferies London Healthcare Conference
-
Athira Pharma Presents Preclinical Data Further Supporting the Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
-
Athira Pharma to Participate in Upcoming October Conferences
-
Athira Pharma to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
-
Athira Pharma Reports Second Quarter 2023 Financial Results and Pipeline and Business Updates
-
Athira Pharma Presents Phase 2 Clinical Data Correlating Improvements in Biomarkers of Neurodegeneration and Neuroinflammation with Improvements in Measures of Cognition and Function in Alzheimer’s
-
Athira Pharma Announces Upcoming Presentations at the Alzheimer’s Association International Conference (AAIC) 2023
-
Athira Pharma to Participate in Upcoming June Conferences
-
Athira Pharma Appoints Andrew Gengos as Chief Financial Officer and Chief Business Officer
-
Athira Pharma Reports First Quarter 2023 Financial Results and Recent Pipeline and Business Updates
-
Athira Pharma to Participate in Upcoming May Investor Conferences
-
Athira Pharma Presents New Clinical and Preclinical Data at the American Academy of Neurology (AAN) 2023 Annual Meeting
-
Athira Pharma Presents New Clinical and Preclinical Data at the American Academy of Neurology (AAN) 2023 Annual Meeting
-
Athira Pharma Announces Upcoming Presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting
-
Athira Pharma Announces Upcoming Presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting
-
Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of Fosgonimeton for Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2023 International Conference
-
Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of Fosgonimeton for Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2023 International Conference
-
Athira Pharma Reports Full Year 2022 Financial Results and Recent Pipeline and Business Updates
-
Athira Pharma Reports Full Year 2022 Financial Results and Recent Pipeline and Business Updates
-
Athira Pharma to Present at Upcoming Neuroscience Focused Investor Conferences
-
Athira Pharma to Present at Upcoming Neuroscience Focused Investor Conferences
-
Athira Pharma to Present Data Supporting Therapeutic Potential of Enhancing HGF/MET Neurotrophic System at Upcoming Scientific Conferences
-
Athira Pharma to Present Data Supporting Therapeutic Potential of Enhancing HGF/MET Neurotrophic System at Upcoming Scientific Conferences
-
Athira Pharma Announces Publication in Journal of Alzheimer’s Disease Highlighting Need for Novel Alzheimer’s Disease Treatment Approaches and Potential of Enhancing HGF/MET Pathway
-
Athira Pharma Announces Publication in Journal of Alzheimer’s Disease Highlighting Need for Novel Alzheimer’s Disease Treatment Approaches and Potential of Enhancing HGF/MET Pathway
-
Athira Pharma Announces Promotion of Kevin Church, Ph.D., to Chief Scientific Officer
-
Athira Pharma Announces Promotion of Kevin Church, Ph.D., to Chief Scientific Officer
-
Athira Pharma Provides 2023 Pipeline Outlook
-
Athira Pharma Provides 2023 Pipeline Outlook
-
Athira Pharma Announces Publication of Fosgonimeton Preclinical Results in Neurotherapeutics
-
Athira Pharma Announces Publication of Fosgonimeton Preclinical Results in Neurotherapeutics
-
Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND
-
Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND
-
Athira Pharma to Host Virtual R&D Event on December 7, 2022, from 2:00 –3:30 pm Eastern time
-
Athira Pharma to Host Virtual R&D Event on December 7, 2022, from 2:00 –3:30 pm Eastern time
-
Athira Pharma Highlights Therapeutic Potential of Fosgonimeton in Presentation of Additional Biomarker Data in Mild-to-Moderate Alzheimer’s Disease Patients from ACT-AD Phase 2 Study at CTAD Confere
Back to ATHA Stock Lookup
